Guardian Asset Advisors LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Guardian Asset Advisors LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 6.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,208 shares of the biopharmaceutical company’s stock after buying an additional 845 shares during the period. Guardian Asset Advisors LLC’s holdings in Pfizer were worth $382,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of PFE. Olistico Wealth LLC bought a new stake in Pfizer in the second quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter worth $29,000. Quarry LP bought a new stake in Pfizer in the second quarter worth $31,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.5 %

PFE traded down $0.45 on Thursday, reaching $29.74. 12,099,506 shares of the company traded hands, compared to its average volume of 37,306,688. Pfizer Inc. has a one year low of $25.20 and a one year high of $33.92. The firm has a fifty day simple moving average of $29.09 and a two-hundred day simple moving average of $28.36. The company has a market cap of $168.52 billion, a P/E ratio of -503.25, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.65%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.